GABAB receptors induce phasic release from medial habenula terminals through activity-dependent recruitment of release-ready vesicles.

GABAB receptor (GBR) activation inhibits neurotransmitter release in axon terminals in the brain, except in medial habenula (MHb) terminals, which show robust potentiation. However, mechanisms underlying this enigmatic potentiation remain elusive. Here, we report that GBR activation on MHb terminals induces an activity-dependent transition from a facilitating, tonic to a depressing, phasic neurotransmitter release mode. This transition is accompanied by a 4.1-fold increase in readily releasable vesicle pool (RRP) size and a 3.5-fold increase of docked synaptic vesicles (SVs) at the presynaptic active zone (AZ). Strikingly, the depressing phasic release exhibits looser coupling distance than the tonic release. Furthermore, the tonic and phasic release are selectively affected by deletion of synaptoporin (SPO) and Ca2+-dependent activator protein for secretion 2 (CAPS2), respectively. SPO modulates augmentation, the short-term plasticity associated with tonic release, and CAPS2 retains the increased RRP for initial responses in phasic response trains. The cytosolic protein CAPS2 showed a SV-associated distribution similar to the vesicular transmembrane protein SPO, and they were colocalized in the same terminals. We developed the "Flash and Freeze-fracture" method, and revealed the release of SPO-associated vesicles in both tonic and phasic modes and activity-dependent recruitment of CAPS2 to the AZ during phasic release, which lasted several minutes. Overall, these results indicate that GBR activation translocates CAPS2 to the AZ along with the fusion of CAPS2-associated SVs, contributing to persistency of the RRP increase. Thus, we identified structural and molecular mechanisms underlying tonic and phasic neurotransmitter release and their transition by GBR activation in MHb terminals.

A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy.

Diabetic cardiomyopathy (DCM) is characterized by structural and functional abnormalities in the myocardium affecting people with diabetes. Treatment of DCM focuses on glucose control, blood pressure management, lipid-lowering, and lifestyle changes. Due to limited therapeutic options, DCM remains a significant cause of morbidity and mortality in patients with diabetes, thus emphasizing the need to develop new therapeutic strategies. Ongoing research is aimed at understanding the underlying molecular mechanism(s) involved in the development and progression of DCM, including oxidative stress, inflammation, and metabolic dysregulation. The goal is to develope innovative pharmaceutical therapeutics, offering significant improvements in the clinical management of DCM. Some of these approaches include the effective targeting of impaired insulin signaling, cardiac stiffness, glucotoxicity, lipotoxicity, inflammation, oxidative stress, cardiac hypertrophy, and fibrosis. This review focuses on the latest developments in understanding the underlying causes of DCM and the therapeutic landscape of DCM treatment.

Histopathological changes and tissue residue concentrations of monosex Nile tilapia (Oreochromis niloticus, L) fries exposed to oxytetracycline.

The current study evaluated the biosafety of oxytetracycline (OTC) exposure for 30 days in monosex Oreochromis niloticus fries. The fries were exposed to OTC for 3 h/day for 30 days at 350 (0.5X), 700 (1X), 2100 (3X), 3500 (5X), and 7000 (10X) mg/L and compared with control (0X). The OTC exposure at 5X and 10X concentrations caused 100% mortality within 4 days and 5 min, respectively. The mortalities recorded in 0.5X, 1X, and 3X groups were 3.33 ± 1.15%, 14.67 ± 1.15%, and 47.33 ± 11.37% on day 30, respectively. The feed intake was decreased up to 23.33% in the 3X group during the exposure period. The OTC residue levels on 30-day exposure were 216.53 ± 14.71, 450.56 ± 44.31, and 1141.26 ± 63.64 µg/kg, which reduced to 40.40 ± 3.25, 76.68 ± 2.77, and 95.61 ± 5.13 µg/kg after 15 days of termination of exposure in the 0.5X, 1X, and 3X groups, respectively. The histopathological changes observed in the 1X group were epithelial detachment, desquamation of secondary lamellar epithelium, lamellar fusion, and inflamed cartilaginous core in the gills, alteration in the integrity of gut mucosa, degeneration of muscularis mucosae and necrosis in the intestine, the disintegration of the nephritic tubule, necrosis, and glomerulopathy in the kidney, and dilated vascular duct, necrotized hepatic tissue, diffused hepatic parenchyma, vacuolation, and fatty changes in the liver. The OTC exposure induced marked tissue changes histologically in a dose- and time-dependent manner, which undoubtedly reduced the growth of tilapia. Supplementary Information: The online version contains supplementary material available at 10.1007/s10499-022-00892-w.

Triclosan exposure induces varying extent of reversible antimicrobial resistance in Aeromonas hydrophila and Edwardsiella tarda.

Triclosan (TCS) is a biocide commonly used in household and personal care items to prevent the microbial growth and is currently considered as an emerging pollutant. It has a ubiquitous distribution which can substantially contribute towards antimicrobial resistance. The present study was designed to evaluate the effect of different concentrations of TCS exposure on the antibiotic sensitivity of aquatic bacteria. Aeromonas hydrophila ATCC® 49140™ and Edwardsiella tarda ATCC® 15947™ exposed to TCS for short (30 min) and long duration (serial passages). The agar-disc diffusion assay during the serial passages of TCS exposure and subsequent exposure withdrawal showed clinically insignificant changes in the zone of inhibition for six selected antibiotics in both bacterial strains at all exposure concentrations. Four folds concentration-dependent increase in the minimum inhibitory concentrations (MICs) of TCS was observed in both the strains following TCS exposure. Similarly, a concentration-dependent increase in the MICs of oxytetracycline (OTC) up to 4 folds in A. hydrophila, and up to 8 folds in E. tarda, was also documented during the TCS exposure. In all the cases, withdrawal of TCS exposure effectively reduced the MICs of TCS and OTC in blank passages suggesting a decline in acquired resistance. The frequencies of mutation during 30 min TCS exposure for E. tarda and A. hydrophila ranged between >10-6 and 10-7 levels. Nevertheless, the TCS exposure did not cause any detectable mutation on the fabV gene of A. hydrophila indicating that the TCS may elicit phenotypic adaptation or other resistance mechanism. Although the reduction in MICs due to exposure withdrawal did not restore the bacterial susceptibility up to the initial level, the study proved that the reduced TCS use could significantly help reduce the antimicrobial-resistance and cross-resistance in pathogenic bacteria.